Fig. 1: Screening MMV Pathogen Box compounds against Theileria-infected macrophages. | Communications Biology

Fig. 1: Screening MMV Pathogen Box compounds against Theileria-infected macrophages.

From: Trifloxystrobin blocks the growth of Theileria parasites and is a promising drug to treat Buparvaquone resistance

Fig. 1

a A schematic presentation of the different steps of the microscopy-based drug screen. T. annulata-infected macrophages (TaC12 cell line) were distributed into 96-well plates and imaged after incubation (48 h) with compounds from the MMV Pathogen Box library at two concentrations. The screen involved identifying and segmentation of host cell nuclei (DAPI staining), the macroschizont membrane (CLASP-GFP fusion protein) and parasite nuclei (H3K18me1 staining). b TaC12 cells treated with MMV Pathogen Box compounds at two concentrations (10 µM or 2 µM) for 48 h. Host cell survival was calculated by comparing the number of host cell nuclei per field with control (DMSO-treated) cells. Results are plotted for percent host cell survival, with the darkest spots representing compounds causing <25% survival. c Comparison of our results with previous MMV screening reports for Theileria-infected cells. The hit compounds from screens conducted against cells infected with T. equi (Van Voorhis et al.4, Nugraha et al.28), T. parva (Nyagwange et al.26) or T. annulata (Hostettler et al.27) are indicated as circles. Hits detected in more than one screen are indicated in dark red. The complete list of compounds is shown in Supplementary Table 1.

Back to article page